Women with mutations in certain genes are predisposed to a high risk of breast cancer (about 50%) up to an age of 70 years. A study published by Dr Benjamin Nisman and colleagues have found that DiviTumTM, Biovicas high-precision test to measure cell growth rate, is important when identifying women with high risk to develop [...]
Sweden’s Innovation Agency publishes article on how DiviTum improves cancer diagnostics (in Swedish). Read the full article here. (PDF)
In the clinical trial collaboration programme between Biovica and Karolinska Institutet, the results from the first study have now been published by the scientific journal Breast Cancer Research and Treatment; http://www.ncbi.nlm.nih.gov/pubmed/23736998. Karolinska Institutet and University Hospital have shown that a simple blood test can predict breast cancer patients response to therapy, how long treatment will be effective and survival. [...]
Karolinska Institutet and University Hospital have shown that a simple blood test can predict breast cancer patients response to therapy
Karolinska Institutet and University Hospital have shown that a simple blood test can predict breast cancer patients response to therapy, how long treatment will be effective and survival. The results are being presented at the IMPAKT scientific conference in Brussels, May 2-4. The analysis measures growth rate and this is the first time ever that one test have documented [...]
Biovica is announced as one of the 33 hottest young tech-companies in Sweden, by the journals Affärsvärlden and Ny Teknik.
Stockholm Business Region, together with the company Avanture, have presented a hotlist for investors with the 20 most attractive life-science companies in the Stockholm-Uppsala area.. Biovica have been appointed as one of the 20 most attractive life-science companies.
The large prostate cancer study STHLM2, conducted by researchers at the Karolinska Institute, has initiated collaboration with Uppsala based bio-diagnostic company Biovica to test whether thymidine kinase is an interesting biomarker for prostate cancer.
Swedish bio-diagnostic company Biovica has signed a three-year, SEK 2.2 million contract with Polish distributor Genoxa. The agreement gives Genoxa the exclusive right to use, sell, distribute and market DiviTum™, Biovicas unique assay for measuring cell-division, in Poland. All together this gives 38 million people access to the most high-tech, scientific cutting-edge assay for measuring [...]
New scientific data published: DiviTum™ delivers valuable new knowledge in patients with lymphatic disease Dr N.K Parilova and colleagues at P-A Herzen, Moscow Oncology Research Institute has studied levels of Thymidine Kinase (TK) measured with DiviTum™ in patients with lymphatic diseases. DiviTum™ demonstrated high diagnostic sensitivity for both lymphatic disease and cancer (Non-Hodgkin’s lymphomas). DiviTum™ [...]
DiviTum™ scientific results presented at the European Heamatology Conference Two abstracts from the University Hospital in Olomouc, Czech Republic presented at the European Heamatology Conference in Amsterdam, June 14-17, demonstrated the value of using DiviTum™ as a prognostic biomarker and it’s unprecedented sensitivity. Dr Prochazka and research colleagues demonstrated that DiviTum™ extends the detection range [...]